Correction: A deacetylase-deficient SIRT1 variant opposes full-length SIRT1 in regulating tumor suppressor p53 and governs expression of cancer-related genes[Molecular and Cellular Biology,(2012),(704-716), 32, 3] https://doi.org/10.1128/MCB.06448-11;A deacetylase-deficient SIRT1 variant opposes full-length SIRT1 in regulating tumor suppressor p53 and governs expression of cancer-related genes

Molecular and Cellular Biology

Volumn 32, Issue 3, 2012, Pages 704-716

  Shah, Zahid H ^a   Ahmed, Shafiq U ^a   Ford, Jack R ^a   Allison, Simon J ^a   Knight, John R P ^a   Milner, Jo ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; CELL LYSATE; CHROMATIN IMMUNOPRECIPITATION; DNA DAMAGE; DNA SPLICING; DOWN REGULATION; EXON; GENE EXPRESSION; GENE SEQUENCE; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RNA INTERFERENCE; RNA TRANSLATION; TUMOR GENE; WILD TYPE;

MAMMALIA;

EID: 84856809261     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00238-17     Document Type: Erratum

References (54)

1. Ahmed SU, Milner J. 2009. Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS One 4:e7305.
2. Allison SL, Stadler K, Mandl CW, Kunz C, Heinz FX. 1995. Synthesisand secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J. Virol. 69:5816 -5820.
3. Asher G, et al. 2008. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 134:317-328.
4. Banks AS, et al. 2008. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab. 8:333-341.
5. Baxter EW, Cummings WJ, Fournier RE. 2005. Formation of a large, complex domain of histone hyperacetylation at human 14q32.1 requires the serpin locus control region. Nucleic Acids Res. 33:3313-3322.
6. Bouras T, et al. 2005. SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1. J. Biol. Chem. 280:10264 -10276.
7. Bourdon JC, et al. 1997. Further characterisation of the p53 responsive element: identification of new candidate genes for trans-activation by p53. Oncogene 14:85-94.
8. Bradbury CA, et al. 2005. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19:1751-1759.
9. Brooks CL, Gu W. 2009. How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer 9:123-128.
10. Buckbinder L, et al. 1995. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377:646-649.
11. Chen D, et al. 2008. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 22:1753-1757.
12. Chen J, Marechal V, Levine AJ. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell. Biol. 13:4107- 4114.
13. Cheng HL, et al. 2003. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 100:10794 -10799.
14. Coussens M, Maresh JG, Yanagimachi R, Maeda G, Allsopp R. 2008. Sirt1 deficiency attenuates spermatogenesis and germ cell function. PLoS One 3:e1571.
15. Das C, Lucia MS, Hansen KC, Tyler JK. 2009. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature 459:113-117.
16. David CJ, Manley JL. 2010. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24:2343-2364.
17. Donmez G, Wang D, Cohen DE, Guarente L. 2010. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142:320 -332.
18. Firestein R, et al. 2008. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3:e2020.
19. Ford J, Ahmed S, Allison S, Jiang M, Milner J. 2008. JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle 7:3091-3097.
20. Ford J, Jiang M, Milner J. 2005. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 65: 10457-10463.
21. Fortin A, et al. 2001. APAF1 is a key transcriptional target for p53 in the regulation of neuronal cell death. J. Cell Biol. 155:207-216.
22. Ghosh HS. 2008. The anti-aging, metabolism potential of SIRT1. Curr. Opin. Invest. Drugs 9:1095-1102.
23. Haigis MC, Guarente LP. 2006. Mammalian sirtuins: emerging roles in physiology, aging, and calorie restriction. Genes Dev. 20:2913-2921.
24. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
25. Hida Y, Kubo Y, Murao K, Arase S. 2007. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch. Dermatol. Res. 299:103-106.
26. Huffman DM, et al. 2007. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67:6612-6618.
27. Knight JR, Milner J. 2012. SIRT1, metabolism and cancer. Curr. Opin. Oncol. 24:68-75.
28. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
29. Kunz C, Pebler S, Otte J, von der Ahe D. 1995. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res. 23:3710-3717.
30. Lavu S, Boss O, Elliott PJ, Lambert PD. 2008. Sirtuins: novel therapeutic targets to treat age-associated diseases. Nat. Rev. Drug Discov. 7:841-853.
31. Luo J, et al. 2001. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 107:137-148.
32. Lynch CJ, Milner J. 2006. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 25:3463-3470.
33. Lynch CJ, et al. 2010. SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53. PLoS One 5:e13502.
34. . 2003. The mammalian SIR2 α protein has a role in embryogenesis and gametogenesis. Mol. Cell. Biol. 23:38-54.
35. Meiller A, et al. 2007. p53-dependent stimulation of redox-related genes in the lymphoid organs of gamma-irradiated: mice identification of haeme-oxygenase 1 as a direct p53 target gene. Nucleic Acids Res. 35: 6924-6934.
36. Milne JC, et al. 2007. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712-716.
37. Motta MC, et al. 2004. Mammalian SIRT1 represses forkhead transcription factors. Cell 116:551-563.
38. Oliner JD, et al. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362:857-860.
39. Peritz T, et al. 2006. Immunoprecipitation of mRNA-protein complexes. Nat. Protoc. 1:577-580.
40. Radisky ES, Radisky DC. 2010. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J. Mammary Gland Biol. Neoplasia 15:201-212.
41. + biosynthesis. Science 324:651-654.
42. Rodgers JT, et al. 2005. Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1. Nature 434:113-118.
43. Rogina B, Helfand SL. 2004. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. U. S. A. 101: 15998-16003.
44. Rubbi CP, Milner J. 2003. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. EMBO J. 22:6068-6077.
45. Shieh SY, Ikeda M, Taya Y, Prives C. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
46. Siliciano JD, et al. 1997. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11:3471-3481.
47. Sinclair DA, Guarente L. 1997. Extrachromosomal rDNA circles: a cause of aging in yeast. Cell 91:1033-1042.
48. Stunkel W, et al. 2007. Function of the SIRT1 protein deacetylase in cancer. Biotechnol. J. 2:1360-1368.
49. Sun Y, Wenger L, Rutter JL, Brinckerhoff CE, Cheung HS. 1999. p53 down-regulates human matrix metalloproteinase-1 (collagenase-1) gene expression. J. Biol. Chem. 274:11535-11540.
50. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. 2009. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 23:1643-1654.
51. Tissenbaum HA, Guarente L. 2001. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature 410:227-230.
52. van der Horst A, et al. 2004. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem. 279:28873-28879.
53. Vaziri H, et al. 2001. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107:149-159.
54. Wang RH, et al. 2008. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14:312-323.